Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Bristol-Myers's Grand Ambitions in Oncology

Related Content

Bristol Rebuilds Oncology Business: Smart Work at FDA Helps

Dec 01 2007

Big Pharma's Leap into Biologics: Bridging both Scientific and Cultural Gaps

Oct 01 2007

End of an Era for GSK and Exelixis

Nov 01 2008

Pfizer's Increasingly Specialist Focus

Nov 01 2008

Eli Lilly's Oncology Focus

Oct 01 2008

UnitedHealth Coverage For Erbitux, Vectibix Premised On KRAS Test Results

Apr 06 2009

Bristol-Myers Squibb Buys Medarex: Adds Eighth ‘Pearl' To String

Jul 27 2009

Bristol's Billion-Dollar Ante to Stay in the Cancer Game

Oct 01 2001

Bristol-Myers Squibb and Otsuka Stabilize Their Bases

Apr 01 2009

Can BMS Deliver on Innovation?

Sep 01 2009

Related Companies

Bristol Myers Squibb Company

Eli Lilly and Company

Roche Holding AG

Genentech, Inc.

Novartis AG

AstraZeneca PLC

Merck KGaA

Vicus Therapeutics

Qiagen NV

Johnson & Johnson

Exelixis, Inc.

GSK plc

MorphoSys AG

Dyax Corp

Genmab A/S

Johns Hopkins University

Pfizer Inc.

Mead Johnson Nutrition Co.

Takeda Pharmaceutical Co. Ltd.

Merck & Co., Inc.

Sanofi

Bristol Myers Squibb Company

Additional Topics

BioPharmaceutical

More from In Vivo Archive

More from In Vivo

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window